Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-05

BIOGEN INC. (BIIB)

CEO Christopher Viehbacher was paid $23,646,004 in fiscal year 2025, ↓ down 2.2% from fiscal year 2024, the 67th percentile of its disclosed peer group (SEC filing 0001193125-26-187303 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$23,646,004 ↓
Christopher Viehbacher total, FY2025
67th
CEO pay percentile vs peers
113:1
CEO-to-median pay ratio
93.67%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Christopher Viehbacher (President and Chief Executive Officer), FY2025 total compensation $23,646,004 (base salary $1,727,885) [exec_comp, SEC accession 0001193125-26-187303, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

BIIB's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗

Page 2 of 35 of the BIOGEN INC. Executive Compensation Report, as it is delivered: Executive Summary.

That is page 2 of 35 of the full Executive Compensation Report, shown as it is delivered. The rest:

  1. Summary Compensation Table
  2. Equity transactions since the proxy statement
  3. Grants of plan-based awards
  4. Outstanding equity awards at fiscal year-end
  5. Incentive-plan design (CD&A)
  6. Say-on-pay
  7. CEO pay ratio
  8. Director compensation
  9. Board fee structure and ownership guideline
  10. Disclosed peer group
  11. Source register

Every figure above cites the filing it came from (accession 0001193125-26-187303, filed 2026-10-05) — see the source register, §11.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Christopher Viehbacher$1,727,885$0$18,368,875$0$3,190,875$0$358,369$23,646,004
President and Chief Executive Officer
Susan Alexander1,028,11105,845,12901,062,21937,718159,3408,132,517
Executive Vice President, Chief Legal Officer
Nicole Murphy909,10905,566,0810977,8280122,4877,575,505
Head of Pharmaceutical Operations and Technology
Priya Singhal929,7128985,566,0810950,8330123,8637,571,387
Head of Development
Robin Kramer759,61704,173,7810788,252084,9345,806,584
Executive Vice President and Chief Financial Officer
Michael McDonnell226,8950000043,955270,850
Former Executive Vice President and Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Christopher Viehbacher$23,646,004$24,166,665$4,069,913↓ −520,661
Susan Alexander8,132,5176,505,8296,703,852↑ +1,626,688
Nicole Murphy7,575,5055,740,3595,714,319↑ +1,835,146
Priya Singhal7,571,3876,387,663—↑ +1,183,724
Robin Kramer5,806,584———
Michael McDonnell270,8506,826,7347,167,601↓ −6,555,884

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read BIOGEN INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BIIB reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the BIOGEN INC. Peer Teardown Report

$23,646,004 Christopher Viehbacher total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 5, 2026 · Source: 0001193125-26-187303 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for BIIB

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
BIIBon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order BIIB

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against BIIB
28 companies name BIIB as a compensation peer

Each company listed discloses BIIB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BIIB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

See BIIB's full peer web, pay-for-performance alignment, and every company benchmarked the same way — start a 3-day trial (no card required)
Or buy the full BIIB Executive Compensation Report ($1,500)

Get the BIOGEN INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Caroline D. DorsaChair of the Board$629,930
Eric K. RowinskyIndependent Director$454,947
Jesus B. MantasIndependent Director$459,947
Lloyd MinorIndependent Director$439,947
Maria C. FreireIndependent Director$457,447
Menelas PangalosIndependent Director$439,947
Monish PatolawalaIndependent Director$447,447
Stephen A. SherwinIndependent Director$439,947
Susan K. LangerIndependent Director$439,947
William A. HawkinsIndependent Director$462,447
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2026-05-01—939——1 insider, 1 accrual row
Adam KeeneyHead of Corporate Development2026-05-01D45518785,112CommonForm 4 ↗
Adam KeeneyHead of Corporate Development2026-05-01A93900CommonForm 4 ↗
Monish PatolawalaDirector2026-06-09A1,50500CommonForm 4 ↗
Susan K. LangerDirector2026-06-09A1,50500CommonForm 4 ↗
Menelas PangalosDirector2026-06-09D2,37000Derivative, Class A CommonForm 4 ↗
Menelas PangalosDirector2026-06-09A2,37000CommonForm 4 ↗
Eric K. RowinskyDirector2026-06-09A1,50500CommonForm 4 ↗
Maria C. FreireDirector2026-06-09A2,00500CommonForm 4 ↗
Jesus B. MantasDirector2026-06-09A1,50500CommonForm 4 ↗
Stephen A. SherwinDirector2026-06-09A1,50500CommonForm 4 ↗
William A. HawkinsDirector2026-06-09A1,50500CommonForm 4 ↗
Menelas PangalosDirector2026-06-09A1,50500CommonForm 4 ↗
Lloyd MinorDirector2026-06-09A1,50500CommonForm 4 ↗
Lloyd MinorDirector2026-08-03D593203120,581CommonForm 4 ↗
Lloyd MinorDirector2026-08-04D593201119,169CommonForm 4 ↗
Michael PariniChief Legal Officer2026-09-01A7,40500Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-10-01—985——1 insider, 1 accrual row
Dividend-equivalent accruals2026-10-02—27——1 insider, 1 accrual row
Sean GodboutChief Accounting Officer2026-10-02D82201,759CommonForm 4 ↗
Sean GodboutChief Accounting Officer2026-10-02A2700CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 21 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Adam KeeneyHead of Corporate Development2026-05-01D939$0$0Derivative, Class A CommonForm 4 ↗
Adam KeeneyHead of Corporate Development2026-05-01D45518785,112CommonForm 4 ↗
Adam KeeneyHead of Corporate Development2026-05-01A93900CommonForm 4 ↗
Monish PatolawalaDirector2026-06-09A1,50500CommonForm 4 ↗
Susan K. LangerDirector2026-06-09A1,50500CommonForm 4 ↗
Menelas PangalosDirector2026-06-09D2,37000Derivative, Class A CommonForm 4 ↗
Menelas PangalosDirector2026-06-09A2,37000CommonForm 4 ↗
Eric K. RowinskyDirector2026-06-09A1,50500CommonForm 4 ↗
Maria C. FreireDirector2026-06-09A2,00500CommonForm 4 ↗
Jesus B. MantasDirector2026-06-09A1,50500CommonForm 4 ↗
Stephen A. SherwinDirector2026-06-09A1,50500CommonForm 4 ↗
William A. HawkinsDirector2026-06-09A1,50500CommonForm 4 ↗
Menelas PangalosDirector2026-06-09A1,50500CommonForm 4 ↗
Lloyd MinorDirector2026-06-09A1,50500CommonForm 4 ↗
Lloyd MinorDirector2026-08-03D593203120,581CommonForm 4 ↗
Lloyd MinorDirector2026-08-04D593201119,169CommonForm 4 ↗
Michael PariniChief Legal Officer2026-09-01A7,40500Derivative, Class A CommonForm 4 ↗
Sean GodboutChief Accounting Officer2026-10-01A98500Derivative, Class A CommonForm 4 ↗
Sean GodboutChief Accounting Officer2026-10-02D2700Derivative, Class A CommonForm 4 ↗
Sean GodboutChief Accounting Officer2026-10-02D82201,759CommonForm 4 ↗
Sean GodboutChief Accounting Officer2026-10-02A2700CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Nicole MurphyPSU2025-02-065,26810,535—21,070$1,499,868
Priya SinghalRSU2025-02-06——14,050—2,000,299
Robin KramerPSU2025-02-061,9757,900—15,8001,549,190
Nicole MurphyRSU2025-02-06——14,050—2,000,299
Susan AlexanderPSU2025-02-062,76611,065—22,1302,169,847
Priya SinghalPSU2025-02-062,63410,535—21,0702,065,914
Christopher ViehbacherPSU2025-02-0617,38534,770—69,5404,950,205
Susan AlexanderPSU2025-02-065,53311,065—22,1301,575,324
Robin KramerPSU2025-02-063,9507,900—15,8001,124,723
Susan AlexanderRSU2025-02-06——14,750—2,099,958
Christopher ViehbacherPSU2025-02-068,69334,770—69,5406,818,397
Priya SinghalPSU2025-02-065,26810,535—21,0701,499,868
Christopher ViehbacherRSU2025-02-06——46,360—6,600,273
Robin KramerRSU2025-02-06——10,535—1,499,868
Nicole MurphyPSU2025-02-062,63410,535—21,0702,065,914
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Nicole Murphy$2,000,299$3,565,782$064.1%
Priya Singhal2,000,2993,565,782064.1%
Robin Kramer1,499,8682,673,913064.1%
Susan Alexander2,099,9583,745,171064.1%
Christopher Viehbacher6,600,27311,768,602064.1%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Priya SinghalPSU1,248—$219,636
Nicole MurphyPSU2,183—384,186
Susan AlexanderPSU2,183—384,186
Nicole MurphyRSU2,102—369,931
Priya SinghalRSU4,434—780,340
Priya SinghalPSU2,495—439,095
Robin KramerRSU789—138,856
Nicole MurphyRSU3,880—682,841
Susan AlexanderRSU3,880—682,841
Nicole MurphyPSU10,535—1,854,055
Robin KramerPSU7,900—1,390,321
Robin KramerRSU10,535—1,854,055
Priya SinghalPSU10,535—1,854,055
Christopher ViehbacherPSU10,133—1,783,307
Robin KramerPSU395—69,516
Christopher ViehbacherPSU34,770—6,119,172
Robin KramerRSU1,407—247,618
Susan AlexanderPSU1,091—192,005
Nicole MurphyPSU1,091—192,005
Christopher ViehbacherRSU18,017—3,170,812
Susan AlexanderPSU11,065—1,947,329
Christopher ViehbacherRSU46,360—8,158,896
Susan AlexanderRSU14,750—2,595,853
Christopher ViehbacherPSU5,066—891,565
Susan AlexanderRSU2,190—385,418
Priya SinghalRSU1,829—321,886
Robin KramerPSU790—139,032
Priya SinghalRSU14,050—2,472,660
Nicole MurphyRSU14,050—2,472,660
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation philosophy is to reward executives for the creation of long-term stockholder value. We design performance-based executive compensation that rewards short-term achievements while maintaining accountability for long-term stockholder value creation. We also seek to maintain competitiveness with our peer group to enable us to attract and retain extraordinary leaders who perform at high levels and succeed in a demanding business environment.

CEO STI target (% of salary)150%
CEO LTI target (% of salary)—
Independent consultantPay Governance
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-09114,184,8167,454,737267,86993.67%Passed
20252025-06-1778,531,75637,113,368364,06267.91%Passed
20242024-06-20114,367,7995,054,473138,35895.77%Passed
20232023-06-2682,640,45436,292,390191,73369.48%Passed
20222022-06-1560,099,27755,305,837493,73051.85%Passed
20212021-06-0259,401,38756,206,0714,667,21849.39%Failed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0993.67%a
20252025-06-1767.91%b
20242024-06-2095.77%c

a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against the proposal, and broker non-votes, if any, will not have any effect on the results of those deliberations.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast under our bylaws and will have no effect on the results of this vote.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast under our bylaws and will have no effect on the results of this vote.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)113 : 1
CEO total compensation$23,646,004
Median employee compensation$208,335
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Caroline D. DorsaIndependent · Board Chair · Compensation and Management Development · Not standing for re-election$230,000$399,930$0$0—$629,930
William A. HawkinsIndependent · Audit · Corporate Governance162,500299,94700—462,447
Jesus B. MantasIndependent · Compensation and Management Development (Chair)155,000299,947005,000459,947
Maria C. FreireIndependent · Corporate Governance · Compensation and Management Development155,000299,947002,500457,447
Eric K. RowinskyIndependent · Compensation and Management Development · Corporate Governance155,000299,94700—454,947
Monish PatolawalaIndependent · Audit (Chair)147,500299,94700—447,447
Lloyd MinorIndependent · Audit140,000299,94700—439,947
Stephen A. SherwinIndependent · Audit140,000299,94700—439,947
Menelas PangalosIndependent · Compensation and Management Development · Newly elected140,000299,94700—439,947
Susan K. LangerIndependent · Compensation and Management Development140,000299,94700—439,947
Christopher A. ViehbacherEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$125,000
Annual equity retainer$300,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)30,000 / 30,000 / 30,000
Stock ownership guideline5x cash retainer (Chair: 5x combined Chair + Board retainer)
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,565,000
Equity awards (grant-date value)$3,099,453
All other compensation$7,500
Total cost of the board$4,671,953

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

AMGN Amgen Inc.INCY Incyte CorporationMRNA Moderna, Inc.REGN Regeneron Pharmaceuticals, Inc.ABBV AbbVie Inc.BMY Bristol-Myers Squibb CompanyJAZZ Jazz Pharmaceuticals plcLLY Eli Lilly and CompanyVRTX Vertex Pharmaceuticals IncorporatedBMRN BioMarin Pharmaceutical Inc.NBIX Neurocrine Biosciences, Inc.GILD Gilead Sciences Inc.ALNY Alnylam Pharmaceuticals, Inc.UTHR United Therapeutics CorporationMRK Merck & Co, Inc.
10a

Peer reciprocity

Of the companies BIOGEN INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

✓ Amgen Inc. (AMGN)77 Incyte Corporation (INCY)✓ Moderna, Inc. (MRNA)78✓ Regeneron Pharmaceuticals, Inc. (REGN)79— AbbVie Inc. (ABBV)80— Bristol-Myers Squibb Company (BMY)81✓ Jazz Pharmaceuticals plc (JAZZ)82— Eli Lilly and Company (LLY)83✓ Vertex Pharmaceuticals Incorporated (VRTX)84✓ BioMarin Pharmaceutical Inc. (BMRN)85✓ Neurocrine Biosciences, Inc. (NBIX)86✓ Gilead Sciences Inc. (GILD)87✓ Alnylam Pharmaceuticals, Inc. (ALNY)88✓ United Therapeutics Corporation (UTHR)89— Merck & Co, Inc. (MRK)90

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including BIOGEN INC..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eli Lilly and Company2025David Ricks$1,700,000$23,325,000$0$6,485,500$36,698,337
2AbbVie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
3Incyte Corporation2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
4Gilead Sciences Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
5Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
6BIOGEN INC.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
7BioMarin Pharmaceutical Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
8Bristol-Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
9Vertex Pharmaceuticals Incorporated2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
10Merck & Co, Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845
11Moderna, Inc.2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
12Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
13United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
14Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
15Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
16Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922——3,682,6557,280,549

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
BIOGEN INC.127%PSU 60 · RSU 40YesPay Governance
AbbVie Inc.not disclosedPSU 40 · PRSU 40 · Option 20Yes — Relative TSRSemler Brossy
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
BioMarin Pharmaceutical Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Bristol-Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Gilead Sciences Inc.180%PSU 50 · Options 25 · RSU 25Yes — Relative TSRFW Cook
Incyte Corporation138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Merck & Co, Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Moderna, Inc.170%PSU 50 · Options 50NoPay Governance LLC
Neurocrine Biosciences, Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSU 40not disclosedPay Governance LLC
United Therapeutics Corporation221%PSO 50 · PSU 50NoAon
Vertex Pharmaceuticals Incorporatednot disclosedPSU 55 · RSU 45Nonot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at BIOGEN INC. in fiscal 2025?
As disclosed, Christopher Viehbacher (President and Chief Executive Officer) was the highest-paid executive at BIOGEN INC. in fiscal 2025, with total compensation of $23,646,004.
How does BIOGEN INC.'s chief executive pay compare to its disclosed peer group?
As disclosed, Christopher Viehbacher's total compensation ranked at the 67th percentile of BIOGEN INC.'s disclosed peer group.
What is BIOGEN INC.'s CEO-to-median employee pay ratio?
As disclosed, BIOGEN INC.'s CEO-to-median employee pay ratio was 113:1.
How did shareholders vote on BIOGEN INC.'s executive compensation?
As disclosed, 93.67% of shareholders supported BIOGEN INC.'s executive compensation in the latest say-on-pay vote.
How much does BIOGEN INC. spend in total on board compensation for fiscal 2025?
As disclosed, BIOGEN INC. reported total board compensation of $4,671,953 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Christopher ViehbacherDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
2Section 01, Susan AlexanderDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 8,132,517. Filing ↗machine: r8 · c16 · span 1183822–1183832
3Section 01, Nicole MurphyDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 7,575,505. Filing ↗machine: r14 · c16 · span 1193928–1193938
4Section 01, Priya SinghalDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 7,571,387. Filing ↗machine: r11 · c16 · span 1189124–1189134
5Section 01, Robin KramerDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 5,806,584. Filing ↗machine: r5 · c16 · span 1179718–1179728
6Section 01, Michael McDonnellDEF 14A2026-04-280001193125-26-187303Section “Summary Compensation Table” · page 52. As printed: 270,850. Filing ↗machine: r17 · c16 · span 1199428–1199436
7Section 03, Nicole Murphy PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1306085–1306095
8Section 03, Priya Singhal RSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1297129–1297139
9Section 03, Robin Kramer PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1265013–1265023
10Section 03, Nicole Murphy RSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1309843–1309853
11Section 03, Susan Alexander PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1277728–1277738
12Section 03, Priya Singhal PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1290442–1290452
13Section 03, Christopher Viehbacher PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1255230–1255240
14Section 03, Susan Alexander PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1280657–1280667
15Section 03, Robin Kramer PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1267941–1267951
16Section 03, Susan Alexander RSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1284415–1284425
17Section 03, Christopher Viehbacher PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1252300–1252310
18Section 03, Priya Singhal PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1293371–1293381
19Section 03, Christopher Viehbacher RSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1258988–1258998
20Section 03, Robin Kramer RSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1271699–1271709
21Section 03, Nicole Murphy PSUDEF 14A1900-01-010001193125-26-187303Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1303156–1303166
22Section 07, pay ratioDEF 14A2026-04-280001193125-26-187303Section “CEO Pay Ratio”. As printed: 113 : 1. Filing ↗machine: span 1592667–1592675
23Section 08, Caroline D. DorsaDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 629,930. Filing ↗machine: t107 · r4 · c8 · span 654809–654856
24Section 08, William A. HawkinsDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 462,447. Filing ↗machine: t107 · r8 · c8 · span 658584–658631
25Section 08, Jesus B. MantasDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 459,947. Filing ↗machine: t107 · r12 · c8 · span 662213–662260
26Section 08, Maria C. FreireDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 457,447. Filing ↗machine: t107 · r6 · c8 · span 656766–656813
27Section 08, Eric K. RowinskyDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 454,947. Filing ↗machine: t107 · r20 · c8 · span 669473–669520
28Section 08, Monish PatolawalaDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 447,447. Filing ↗machine: t107 · r18 · c8 · span 667657–667704
29Section 08, Lloyd MinorDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 439,947. Filing ↗machine: t107 · r14 · c8 · span 664024–664071
30Section 08, Stephen A. SherwinDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 439,947. Filing ↗machine: t107 · r22 · c8 · span 671610–671657
31Section 08, Menelas PangalosDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 439,947. Filing ↗machine: t107 · r16 · c8 · span 665840–665887
32Section 08, Susan K. LangerDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 439,947. Filing ↗machine: t107 · r10 · c8 · span 660399–660446
33Section 08, Christopher A. ViehbacherDEF 14A2026-04-280001193125-26-187303Section “Director Compensation”. As printed: 0. Filing ↗
34Section 02, Adam Keeney 2026-05-01Form 42026-05-050000875045-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Adam Keeney 2026-05-01Form 42026-05-050000875045-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Adam Keeney 2026-05-01Form 42026-05-050000875045-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Monish Patolawala 2026-06-09Form 42026-06-110000875045-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Susan K. Langer 2026-06-09Form 42026-06-110000875045-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Menelas Pangalos 2026-06-09Form 42026-06-110000875045-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Menelas Pangalos 2026-06-09Form 42026-06-110000875045-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Eric K. Rowinsky 2026-06-09Form 42026-06-110000875045-26-000063Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Maria C. Freire 2026-06-09Form 42026-06-110000875045-26-000052Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Jesus B. Mantas 2026-06-09Form 42026-06-110000875045-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Stephen A. Sherwin 2026-06-09Form 42026-06-110000875045-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, William A. Hawkins 2026-06-09Form 42026-06-110000875045-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Menelas Pangalos 2026-06-09Form 42026-06-110000875045-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Lloyd Minor 2026-06-09Form 42026-06-110000875045-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Lloyd Minor 2026-08-03Form 42026-08-050000875045-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Lloyd Minor 2026-08-04Form 42026-08-050000875045-26-000076Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Michael Parini 2026-09-01Form 42026-09-030000875045-26-000082Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Sean Godbout 2026-10-01Form 42026-10-050000875045-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Sean Godbout 2026-10-02Form 42026-10-050000875045-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Sean Godbout 2026-10-02Form 42026-10-050000875045-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Sean Godbout 2026-10-02Form 42026-10-050000875045-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
55Section 06, 2026 voteForm 8-K2026-06-100000950157-26-000700Item 5.07 · say-on-pay result. As reported: 93.67% (votes for as printed: 114,184,816). Filing ↗
56Section 06, 2025 voteForm 8-K2025-06-230000875045-25-000023Item 5.07 · say-on-pay result. As reported: 67.91% (votes for as printed: 78,531,756). Filing ↗
57Section 06, 2024 voteForm 8-K2024-06-250001193125-24-167938Item 5.07 · say-on-pay result. As reported: 95.77% (votes for as printed: 114,367,799). Filing ↗
58Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
59Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
60Section 09b board cost (computed)Computed——Cash 1,565,000 + equity 3,099,453 + all other 7,500 = 4,671,953, summed across the director compensation table rows.machine: formula: Σ = 4,671,953
61Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
62AbbVie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. Filing ↗
63Incyte Corporation, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
64Gilead Sciences Inc., Section 10b CEO totalDEF 14A2026-03-200001308179-26-000106CEO total compensation as printed in Gilead Sciences Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592
65Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
66BIOGEN INC. (subject), Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in BIOGEN INC.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
67BioMarin Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
68Bristol-Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
69Vertex Pharmaceuticals Incorporated, Section 10b CEO totalDEF 14A2026-04-020000875320-26-000153CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809
70Merck & Co, Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck & Co, Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
71Moderna, Inc., Section 10b CEO totalDEF 14A2026-03-160001308179-26-000081CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898
72Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
73United Therapeutics Corporation, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
74Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
75Neurocrine Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
76Regeneron Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001308179-26-000340CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989
77Section 10a, Amgen Inc. reciprocityDEF 14A—0001193125-26-145588Amgen Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
78Section 10a, Moderna, Inc. reciprocityDEF 14A—0001308179-26-000081Moderna, Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
79Section 10a, Regeneron Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000340Regeneron Pharmaceuticals, Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
80Section 10a, AbbVie Inc. reciprocityDEF 14A—0001104659-26-033387AbbVie Inc.'s most recent proxy was read; its disclosed peer group does not include BIOGEN INC.. Filing ↗
81Section 10a, Bristol-Myers Squibb Company reciprocityDEF 14A—0000014272-26-000006Bristol-Myers Squibb Company's most recent proxy was read; its disclosed peer group does not include BIOGEN INC.. Filing ↗
82Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals plc names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
83Section 10a, Eli Lilly and Company reciprocityDEF 14A—0000059478-26-000029Eli Lilly and Company's most recent proxy was read; its disclosed peer group does not include BIOGEN INC.. Filing ↗
84Section 10a, Vertex Pharmaceuticals Incorporated reciprocityDEF 14A—0000875320-26-000153Vertex Pharmaceuticals Incorporated names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
85Section 10a, BioMarin Pharmaceutical Inc. reciprocityDEF 14A—0001628280-26-026290BioMarin Pharmaceutical Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
86Section 10a, Neurocrine Biosciences, Inc. reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences, Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
87Section 10a, Gilead Sciences Inc. reciprocityDEF 14A—0001308179-26-000106Gilead Sciences Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
88Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-023923Alnylam Pharmaceuticals, Inc. names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, United Therapeutics Corporation reciprocityDEF 14A—0001082554-26-000009United Therapeutics Corporation names BIOGEN INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
90Section 10a, Merck & Co, Inc. reciprocityDEF 14A—0001193125-26-147704Merck & Co, Inc.'s most recent proxy was read; its disclosed peer group does not include BIOGEN INC.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the BIOGEN INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
BIIB Peer Teardown Report